KR100330325B1 - 감마인터페론의안정한액체조성물 - Google Patents

감마인터페론의안정한액체조성물 Download PDF

Info

Publication number
KR100330325B1
KR100330325B1 KR1019950705034A KR19950705034A KR100330325B1 KR 100330325 B1 KR100330325 B1 KR 100330325B1 KR 1019950705034 A KR1019950705034 A KR 1019950705034A KR 19950705034 A KR19950705034 A KR 19950705034A KR 100330325 B1 KR100330325 B1 KR 100330325B1
Authority
KR
South Korea
Prior art keywords
ifn
composition
gamma
preservative
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1019950705034A
Other languages
English (en)
Korean (ko)
Other versions
KR960702320A (ko
Inventor
튜 느구옌
Original Assignee
제넨테크, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제넨테크, 인코포레이티드 filed Critical 제넨테크, 인코포레이티드
Publication of KR960702320A publication Critical patent/KR960702320A/ko
Application granted granted Critical
Publication of KR100330325B1 publication Critical patent/KR100330325B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1019950705034A 1993-05-12 1994-05-04 감마인터페론의안정한액체조성물 Expired - Lifetime KR100330325B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6032793A 1993-05-12 1993-05-12
US08/060327 1993-05-12
PCT/US1994/004928 WO1994026302A1 (en) 1993-05-12 1994-05-04 Stable liquid compositions of gamma interferon

Publications (2)

Publication Number Publication Date
KR960702320A KR960702320A (ko) 1996-04-27
KR100330325B1 true KR100330325B1 (ko) 2002-11-01

Family

ID=22028807

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950705034A Expired - Lifetime KR100330325B1 (ko) 1993-05-12 1994-05-04 감마인터페론의안정한액체조성물

Country Status (22)

Country Link
EP (1) EP0697887B1 (cg-RX-API-DMAC7.html)
JP (1) JP4053586B2 (cg-RX-API-DMAC7.html)
KR (1) KR100330325B1 (cg-RX-API-DMAC7.html)
CN (1) CN1120724C (cg-RX-API-DMAC7.html)
AT (1) ATE173632T1 (cg-RX-API-DMAC7.html)
AU (1) AU683469B2 (cg-RX-API-DMAC7.html)
CA (1) CA2159602C (cg-RX-API-DMAC7.html)
CZ (1) CZ285389B6 (cg-RX-API-DMAC7.html)
DE (1) DE69414841T2 (cg-RX-API-DMAC7.html)
DK (1) DK0697887T3 (cg-RX-API-DMAC7.html)
ES (1) ES2126114T3 (cg-RX-API-DMAC7.html)
FI (1) FI111442B (cg-RX-API-DMAC7.html)
GR (1) GR3029286T3 (cg-RX-API-DMAC7.html)
HU (1) HUT72980A (cg-RX-API-DMAC7.html)
IL (1) IL109350A (cg-RX-API-DMAC7.html)
NO (1) NO320069B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ266354A (cg-RX-API-DMAC7.html)
PL (1) PL176079B1 (cg-RX-API-DMAC7.html)
SK (1) SK280958B6 (cg-RX-API-DMAC7.html)
TW (1) TW275585B (cg-RX-API-DMAC7.html)
WO (1) WO1994026302A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA942955B (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW426523B (en) * 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
US6964947B1 (en) 1995-11-07 2005-11-15 Genentech, Inc. Stabilizing formulation for NGF
JP4057058B2 (ja) * 1995-11-07 2008-03-05 ジェネンテック インコーポレーテッド Ngfの安定化処方
US6090781A (en) * 1996-11-06 2000-07-18 Genentech, Inc. Stabilizing formulation for NGF
JP3493866B2 (ja) * 1995-12-27 2004-02-03 ライオン株式会社 発泡性口腔用組成物
PE63998A1 (es) * 1996-04-19 1998-10-30 Merck & Co Inc Composiciones anti-fungosas
JP2000516210A (ja) 1996-07-12 2000-12-05 ロイコサイト,インコーポレーテッド ケモカインレセプターアンタゴニストとその使用方法
DE69729880T3 (de) * 1996-12-24 2012-05-10 Biogen Idec Ma Inc. Stabile flüssige interferon-zubereitungen
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US7070799B1 (en) 1998-02-10 2006-07-04 Generex Pharmaceuticals, Inc. Method for administering insulin to the buccal region
US6017545A (en) * 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation
US6221378B1 (en) * 1998-02-10 2001-04-24 Generex Pharmaceuticals Incorporated Mixed micellar delivery system and method of preparation
GB9803448D0 (en) * 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
AU4445201A (en) * 2000-03-30 2001-10-08 Generex Pharmaceuticals Inc. Method for administering insulin to the buccal region
AUPR381601A0 (en) * 2001-03-19 2001-04-12 Monash University Method of treating respiratory conditions
EP1391209A4 (en) * 2001-05-30 2009-12-16 Chugai Pharmaceutical Co Ltd PROTEIN PREPARATION
EP1516627A1 (en) * 2003-09-17 2005-03-23 CONARIS research institute AG Interferon-Gamma for the treatment of diseases associated with the NOD2 gene
JP5137055B2 (ja) * 2006-03-10 2013-02-06 塩野義製薬株式会社 安定化されたインターフェロン−γ組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0257956A2 (en) * 1986-08-19 1988-03-02 Genentech, Inc. Device and dispersion for intrapulmonary delivery of polypeptide growth factors and cytokines

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT88490B (pt) * 1987-09-14 1992-11-30 Novo Nordisk As Processo para a preparacao de composicoes farmaceuticas para libertacao nao-enterica trans-mucosa contendo monossacaridos ou oligossacaridos
IL88233A (en) * 1987-11-03 1993-08-18 Genentech Inc Gamma interferon formulation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0257956A2 (en) * 1986-08-19 1988-03-02 Genentech, Inc. Device and dispersion for intrapulmonary delivery of polypeptide growth factors and cytokines

Also Published As

Publication number Publication date
DK0697887T3 (da) 1999-08-09
WO1994026302A1 (en) 1994-11-24
CZ285389B6 (cs) 1999-07-14
DE69414841T2 (de) 1999-06-02
KR960702320A (ko) 1996-04-27
ZA942955B (en) 1995-10-30
SK280958B6 (sk) 2000-10-09
JP4053586B2 (ja) 2008-02-27
FI955136L (fi) 1995-10-27
IL109350A0 (en) 1994-07-31
HU9503223D0 (en) 1996-01-29
PL311639A1 (en) 1996-03-04
PL176079B1 (pl) 1999-04-30
GR3029286T3 (en) 1999-05-28
TW275585B (cg-RX-API-DMAC7.html) 1996-05-11
CA2159602C (en) 2008-08-26
ATE173632T1 (de) 1998-12-15
NO954544L (no) 1995-11-10
CZ295595A3 (en) 1996-04-17
JPH08510242A (ja) 1996-10-29
EP0697887A1 (en) 1996-02-28
AU6782294A (en) 1994-12-12
HK1008303A1 (en) 1999-05-07
NO320069B1 (no) 2005-10-17
FI111442B (fi) 2003-07-31
CN1120724C (zh) 2003-09-10
NO954544D0 (no) 1995-11-10
DE69414841D1 (de) 1999-01-07
IL109350A (en) 2001-01-28
FI955136A0 (fi) 1995-10-27
HUT72980A (en) 1996-06-28
EP0697887B1 (en) 1998-11-25
AU683469B2 (en) 1997-11-13
CA2159602A1 (en) 1994-11-24
SK137895A3 (en) 1997-02-05
CN1122575A (zh) 1996-05-15
NZ266354A (en) 1997-06-24
ES2126114T3 (es) 1999-03-16

Similar Documents

Publication Publication Date Title
CA2159602C (en) Stable liquid compositions of gamma interferon
EP1417972B2 (en) Stabilized teriparatide solutions
ES2286868T3 (es) Composicion acuosa a base de hormana del crecimiento humana.
EP2586459B1 (en) Vegf antagonist formulations
ES2224290T3 (es) Formulaciones liquidas estables de interferon.
US9522174B2 (en) Stable liquid interferon beta formulations
AU2005249233B2 (en) Stabilized interferon liquid formulations
NZ226791A (en) Liquid pharmaceutical composition comprising non-lyophilised gamma-interferon
HK1008303B (en) Stable liquid compositions of gamma interferon
HK1184680B (en) Vegf antagonist formulations
HK1025040B (en) Stable liquid interferon formulations

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19951111

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19990504

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20010530

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20020122

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20020314

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20020315

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20050309

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20060313

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20070313

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20080310

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20090311

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20100310

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20110210

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20120220

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20130227

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20130227

Start annual number: 12

End annual number: 12

FPAY Annual fee payment

Payment date: 20140227

Year of fee payment: 13

PR1001 Payment of annual fee

Payment date: 20140227

Start annual number: 13

End annual number: 13

EXPY Expiration of term
PC1801 Expiration of term

Termination date: 20141104

Termination category: Expiration of duration